Date: 2014-03-01
Type of information: Nomination
Compound: chief medical officer
Company: Canbex Therapeutics (UK)
Therapeutic area: CNS diseases - Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 1st, 2014, Canbex Therapeutics announced the appointment of Dr Alberto Lledó as its new chief medical officer, effective immediately. Dr Lledó will lead Canbex’s preparations for Proof of Concept trials for VSN16R, its orally active small molecule intended for the treatment of spasticity in multiple sclerosis.
Dr Lledó is Senior Consultant Neurologist at Clínica Creu Blanca, Barcelona, and spent sixteen years at Eli Lilly in roles that included Global Senior Medical Advisor and CNS Clinical Research Physician for Europe, with responsibilities that encompassed the co-ordination in Europe of Phase II clinical trials for compounds in the Neurology pipeline.
Canbex has successfully completed the Single Ascending Dose (SAD) stage of its Phase I study of VSN16R, with highly encouraging results. The Multiple Ascending Dose (MAD) part of the trial is due to start imminently. The first-in-man study of VSN16R is enrolling a total of 72 healthy volunteers and is being carried out by Quintiles,.
Dr Lledó will take over as CMO from Dr Miroslav Ravic, who is successfully guiding the company through completion of its Phase I study.
Financial terms:
Latest news:
Is general: Yes
